Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline.

Tytuł:
Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline.
Autorzy:
Asanad S; Doheny Eye Institute, Los Angeles, CA, United States of America.; Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America.
Fantini M; Doheny Eye Institute, Los Angeles, CA, United States of America.; Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America.; Department of Medicine, Ophthalmology, University of Udine, Udine, Italy.
Sultan W; Doheny Eye Institute, Los Angeles, CA, United States of America.
Nassisi M; Doheny Eye Institute, Los Angeles, CA, United States of America.; Department of Clinical Sciences and Community Health, Ophthalmological Unit, IRCCS-Cà Granda Foundation-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Felix CM; Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America.
Wu J; Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America.
Karanjia R; Doheny Eye Institute, Los Angeles, CA, United States of America.; Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America.; Department of Ophthalmology, University of Ottawa, Ottawa, Ontario, Canada.; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Ross-Cisneros FN; Doheny Eye Institute, Los Angeles, CA, United States of America.
Sagare AP; Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States of America.
Zlokovic BV; Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States of America.
Chui HC; Department of Neurology, University of Southern California, Los Angeles, CA, United States of America.
Pogoda JM; Cipher Biostatistics & Reporting, Reno, NV, United States of America.
Arakaki X; Huntington Medical Research Institutes, Pasadena, CA, United States of America.
Fonteh AN; Huntington Medical Research Institutes, Pasadena, CA, United States of America.
Sadun AA; Doheny Eye Institute, Los Angeles, CA, United States of America.; Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America.
Harrington MG; Huntington Medical Research Institutes, Pasadena, CA, United States of America.
Źródło:
PloS one [PLoS One] 2020 May 29; Vol. 15 (5), pp. e0232785. Date of Electronic Publication: 2020 May 29 (Print Publication: 2020).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:
Alzheimer Disease/*genetics
Amyloid beta-Peptides/*genetics
Cognitive Dysfunction/*genetics
tau Proteins/*genetics
Aged ; Aged, 80 and over ; Alzheimer Disease/cerebrospinal fluid ; Alzheimer Disease/diagnostic imaging ; Alzheimer Disease/pathology ; Amyloid beta-Peptides/cerebrospinal fluid ; Amyloidosis/cerebrospinal fluid ; Amyloidosis/diagnostic imaging ; Amyloidosis/genetics ; Amyloidosis/pathology ; Biomarkers/cerebrospinal fluid ; Cognitive Dysfunction/cerebrospinal fluid ; Cognitive Dysfunction/diagnostic imaging ; Cognitive Dysfunction/pathology ; Female ; Humans ; Male ; Middle Aged ; Nerve Fibers/metabolism ; Nerve Fibers/pathology ; Optic Disk/diagnostic imaging ; Optic Disk/metabolism ; Optic Disk/pathology ; Retina/diagnostic imaging ; Retina/metabolism ; Retina/pathology ; Retinal Ganglion Cells/metabolism ; Retinal Ganglion Cells/pathology ; Tomography, Optical Coherence ; tau Proteins/cerebrospinal fluid
References:
Surv Ophthalmol. 2014 Jul-Aug;59(4):414-33. (PMID: 24309127)
Am J Alzheimers Dis Other Demen. 2016 Aug;31(5):430-6. (PMID: 26888864)
Arch Neurol. 2012 Feb;69(2):215-22. (PMID: 22332188)
Clin Neurol Neurosurg. 2011 Sep;113(7):523-6. (PMID: 21454010)
Invest Ophthalmol Vis Sci. 2006 Feb;47(2):626-33. (PMID: 16431960)
Front Cell Neurosci. 2013 Sep 19;7:142. (PMID: 24065883)
Invest Ophthalmol Vis Sci. 2013 Sep 05;54(9):5953-8. (PMID: 23920375)
J Alzheimers Dis. 2014;40(2):277-83. (PMID: 24413621)
Med Clin North Am. 2013 May;97(3):439-57. (PMID: 23642580)
Clin Neurophysiol. 2001 Oct;112(10):1860-7. (PMID: 11595144)
J Alzheimers Dis. 2015;45(1):45-56. (PMID: 25428254)
PLoS One. 2012;7(12):e53547. (PMID: 23300938)
J Neuroophthalmol. 2006 Mar;26(1):18-24. (PMID: 16518161)
BMC Neurol. 2015 Feb 21;15:14. (PMID: 25886372)
Acta Neuropathol. 2016 Dec;132(6):767-787. (PMID: 27645291)
Curr Alzheimer Res. 2014 Mar;11(3):259-66. (PMID: 24484274)
PLoS One. 2018 Feb 8;13(2):e0192646. (PMID: 29420642)
Alzheimers Dement (Amst). 2015 Apr 23;1(2):136-43. (PMID: 27239501)
Neurology. 2013 Jul 2;81(1):76-83. (PMID: 23709591)
Invest Ophthalmol Vis Sci. 2007 May;48(5):2285-9. (PMID: 17460292)
Alzheimers Dement (Amst). 2015 Apr 23;1(2):144-51. (PMID: 27239502)
Neuroreport. 2011 Aug 24;22(12):623-7. (PMID: 21734608)
Neurol Sci. 2015 Jul;36(7):1141-6. (PMID: 25575807)
J Gen Intern Med. 1991 Mar-Apr;6(2):126-32. (PMID: 2023019)
Neurosci Lett. 2011 Mar 17;491(2):122-6. (PMID: 21236314)
Am J Ophthalmol. 2011 Jan;151(1):85-92.e1. (PMID: 20970108)
Sci Transl Med. 2011 Apr 6;3(77):77sr1. (PMID: 21471435)
Acta Ophthalmol. 2016 Sep;94(6):e454-9. (PMID: 26895692)
Ann Neurol. 2016 Jan;79(1):90-109. (PMID: 26505992)
Dement Geriatr Cogn Disord. 2009;27(6):501-7. (PMID: 19451717)
Acta Ophthalmol. 2019 Dec;97(8):798-804. (PMID: 31058465)
Neurosci Lett. 2010 Aug 9;480(1):69-72. (PMID: 20609426)
Alzheimers Dement (Amst). 2018 Feb 07;10:196-209. (PMID: 29780864)
Arch Gerontol Geriatr. 2015 Jan-Feb;60(1):162-7. (PMID: 25459918)
Exp Aging Res. 2013;39(4):382-97. (PMID: 23875837)
Nat Rev Neurol. 2013 Jan;9(1):54-8. (PMID: 23183885)
Arch Neurol. 2009 Mar;66(3):382-9. (PMID: 19273758)
J Neuroophthalmol. 2013 Mar;33(1):58-61. (PMID: 22918296)
Alzheimers Dement (Amst). 2019 Sep 25;11:659-669. (PMID: 31667327)
PLoS One. 2016 Sep 06;11(9):e0162202. (PMID: 27598262)
Front Psychiatry. 2014 Feb 25;5:22. (PMID: 24616709)
Arch Gerontol Geriatr. 2009;49 Suppl 1:237-43. (PMID: 19836639)
Invest Ophthalmol Vis Sci. 2011 Oct 21;52(11):8323-9. (PMID: 21917932)
Front Cell Neurosci. 2016 Feb 04;10:20. (PMID: 26869887)
PLoS One. 2016 Apr 22;11(4):e0153830. (PMID: 27104962)
Am J Ophthalmol. 1987 Aug 15;104(2):113-20. (PMID: 3618708)
Int J Neurosci. 2018 Sep;128(9):849-853. (PMID: 29447481)
PLoS One. 2015 Aug 07;10(8):e0134750. (PMID: 26252902)
Wiley Interdiscip Rev Syst Biol Med. 2009 Nov-Dec;1(3):380-389. (PMID: 20836003)
Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1491-1500. (PMID: 30973577)
Neurosci Lett. 2007 Jun 13;420(2):97-9. (PMID: 17543991)
Front Neurol. 2016 Apr 19;7:55. (PMID: 27148157)
Mol Neurodegener. 2017 Aug 3;12(1):58. (PMID: 28774322)
J Neurol. 2014 Aug;261(8):1522-30. (PMID: 24846203)
PLoS One. 2013 Nov 18;8(11):e79378. (PMID: 24260210)
Surv Ophthalmol. 1989 Jul-Aug;34(1):31-43. (PMID: 2678551)
Ophthalmic Surg Lasers Imaging Retina. 2015 Mar;46(3):310-4. (PMID: 25856815)
Alzheimers Dement. 2020 Jan;16(1):229-243. (PMID: 31914225)
Neuroimage. 2011 Jan;54 Suppl 1:S204-17. (PMID: 20550967)
N Engl J Med. 1986 Aug 21;315(8):485-7. (PMID: 3736630)
Neurology. 2002 Nov 26;59(10):1594-9. (PMID: 12451203)
Grant Information:
UL1 TR001855 United States TR NCATS NIH HHS; P50 AG005142 United States AG NIA NIH HHS; P01 AG052350 United States AG NIA NIH HHS
Substance Nomenclature:
0 (Amyloid beta-Peptides)
0 (Biomarkers)
0 (tau Proteins)
Entry Date(s):
Date Created: 20200530 Date Completed: 20200731 Latest Revision: 20210408
Update Code:
20240105
PubMed Central ID:
PMC7259639
DOI:
10.1371/journal.pone.0232785
PMID:
32469871
Czasopismo naukowe
Background: Alzheimer's disease (AD) pathology precedes symptoms and its detection can identify at-risk individuals who may benefit from early treatment. Since the retinal nerve fiber layer (RNFL) is depleted in established AD, we tested whether its thickness can predict whether cognitively healthy (CH) individuals have a normal or pathological cerebrospinal fluid (CSF) Aß42 (A) and tau (T) ratio.
Methods: As part of an ongoing longitudinal study, we enrolled CH individuals, excluding those with cognitive impairment and significant ocular pathology. We classified the CH group into two sub-groups, normal (CH-NAT, n = 16) or pathological (CH-PAT, n = 27), using a logistic regression model from the CSF AT ratio that identified >85% of patients with a clinically probable AD diagnosis. Spectral-domain optical coherence tomography (OCT) was acquired for RNFL, ganglion cell-inner plexiform layer (GC-IPL), and macular thickness. Group differences were tested using mixed model repeated measures and a classification model derived using multiple logistic regression.
Results: Mean age (± standard deviation) in the CH-PAT group (n = 27; 75.2 ± 8.4 years) was similar (p = 0.50) to the CH-NAT group (n = 16; 74.1 ± 7.9 years). Mean RNFL (standard error) was thinner in the CH-PAT group by 9.8 (2.7) μm; p < 0.001. RNFL thickness classified CH-NAT vs. CH-PAT with 87% sensitivity and 56.3% specificity.
Conclusions: Our retinal data predict which individuals have CSF biomarkers of AD pathology before cognitive deficits are detectable with 87% sensitivity. Such results from easy-to-acquire, objective and non-invasive measurements of the RNFL merit further study of OCT technology to monitor or screen for early AD pathology.
Competing Interests: The authors have declared that no competing interests exist.
Erratum in: PLoS One. 2020 Jul 14;15(7):e0236379. (PMID: 32663228)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies